Markets:

Overview

News

Currencies

International

Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

101.97 -0.43 (-0.42%)

Streaming Delayed Price Updated: 9:52 AM EDT, Jul 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

Today 0:39 EDT

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Topics Energy

1 High-Flying Stock to Target This Week and 2 Facing Headwinds

July 02, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Via StockStory

Topics Initial Public Offering

1 Russell 2000 Stock with Exciting Potential and 2 We Find Risky

June 29, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

Topics Firearms

LeMaitre Vascular Inc. (NASDAQ:LMAT) Passes the Quality Test with Caviar Cruise Screen ↗

June 24, 2026

Via Chartmill

LeMaitre Vascular Inc (NASDAQ:LMAT): A Quality Investing Candidate Passing All Caviar Cruise Screen Tests ↗

May 13, 2026

Via Chartmill

LeMaitre Vascular (NASDAQ:LMAT) Reports Steady Q1 2026 Results with Earnings Beat and In-Line Revenue ↗

May 05, 2026

Via Chartmill

Topics Earnings

Minervini Watchlist April 24, 2026 - Before Market Open ↗

April 24, 2026

Via Chartmill

LeMaitre Vascular Inc (NASDAQ:LMAT) Passes Key Quality Investing Screens ↗

March 17, 2026

Via Chartmill

3 of Wall Street’s Favorite Stocks We Find Risky

June 02, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Topics Electric Vehicles

1 Reason to Avoid LMAT and 1 Stock to Buy Instead

May 21, 2026

LeMaitre has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15.5% to $101.53 ...

Via StockStory

Topics Artificial Intelligence Stocks Supply Chain

Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

May 18, 2026

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, includ...

Via StockStory

Topics Artificial Intelligence Economy

3 Healthcare Stocks with Open Questions

May 14, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...

Via StockStory

Topics Retirement

5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call

May 12, 2026

LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns o...

Via StockStory

Topics Earnings

1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid

May 07, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Via StockStory

LMAT Q1 Deep Dive: Artegraft Expansion and Pricing Drive, Margin Upside Meets Cautious Market

May 06, 2026

Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio...

Via StockStory

LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates

May 05, 2026

Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio...

Via StockStory

LeMaitre (LMAT) Q1 Earnings Report Preview: What To Look For

May 03, 2026

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market hours. Here’s what you need to know. LeMaitre beat...

Via StockStory

Topics Artificial Intelligence

3 Hyped Up Stocks Walking a Fine Line

April 22, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

3 Cash-Heavy Stocks Walking a Fine Line

April 20, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

Via StockStory

Surgical Equipment & Consumables - Specialty Stocks Q4 Earnings: LeMaitre (NASDAQ:LMAT) Firing on All Cylinders

April 15, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - spe...

Via StockStory

Topics Artificial Intelligence Economy

3 Russell 2000 Stocks We Steer Clear Of

April 07, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K ↗

March 28, 2026

This medical device innovator, focused on vascular surgery solutions, reported a notable insider sale amid steady financial performance.

Via The Motley Fool

Topics Regulatory Compliance

LeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should Know ↗

March 27, 2026

LeMaitre Vascular, a specialist in vascular medical devices, reported a notable insider sale amid strong recent share gains.

Via The Motley Fool

Topics Regulatory Compliance

Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Government Stocks

3 Unpopular Stocks We’re Skeptical Of

March 20, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

3 Cash-Producing Stocks with Warning Signs

March 16, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

3 Healthcare Stocks We’re Skeptical Of

March 13, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

2 Profitable Stocks with Exciting Potential and 1 We Turn Down

March 04, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key...

Via StockStory

Topics Economy Government Stocks

LeMaitre (LMAT) Stock Trades Up, Here Is Why

February 26, 2026

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 16.8% in the morning session after the company reported strong fourth-quarter 2025 results that surpassed Wall Street's...

Via StockStory

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.